Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells

Journal of Experimental Medicine

Volumn 199, Issue 11, 2004, Pages 1503-1511

  Paczesny, Sophie ^a   Banchereau, Jacques ^a   Wittkowski, Knut M ^c   Saracino, Giovanna ^b   Fay, Joseph ^a   Palucka, A Karolina ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cancer; Immunomonitoring; Immunotherapy; Tumor immunology; Vaccine

Indexed keywords

CANCER VACCINE; CD34 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HISTOCOMPATIBILITY ANTIGEN; PEPTIDE;

ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CELL KILLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOMA; MELANOMA CELL; MEMORY CELL; METASTASIS; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY; VACCINATION;

ANTIGENS, CD34; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; MELANOMA; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 2942644555     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20032118     Document Type: Article

References (53)

1. Greenberg, P.D., J.P. Klarnet, D.E. Kern, and M.A. Cheever. 1988. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog. Exp. Tumor Res. 32:104-127.
2. Herlyn, D., A. Linnenbach, H. Koprowski, and M. Herlyn. 1991. Epitope- and antigen-specific cancer vaccines. Int. Rev. Immunol. 7:245-257.
3. North, R.J. 1984. The murine antitumor immune response and its therapeutic manipulation. Adv. Immunol. 35:89-155.
4. Boon, T., J.C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-365.
5. Houghton, A.N. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4.
6. Nagorsen, D., C. Scheibenbogen, F.M. Marincola, A. Letsch, and U. Keilholz. 2003. Natural T cell immunity against cancer. Clin. Cancer Res. 9:4296-4303.
7. Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:175-182.
8. Urban, J.L., and H. Schreiber. 1992. Tumor antigens. Annu. Rev. Immunol. 10:617-644.
9. Kiessling, R., K. Wasserman, S. Horiguchi, K. Kono, J. Sjoberg, P. Pisa, and M. Petersson. 1999. Tumor-induced immune dysfunction. Cancer Immunol. Immunother. 48:353-362.
10. Klein, G., and T. Boon. 1993. Tumor immunology: present perspectives. Curr. Opin. Immunol. 5:687-692.
11. Dudley, M.E., and S.A. Rosenberg. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer. 3:666-675.
12. Hirshaut, Y., and S.F. Slovin. 1985. Harnessing T-lymphocytes for human cancer immunotherapy. Cancer. 56:1366-1373.
13. Melief, C.J., and W.M. Kast. 1991. T-cell immunotherapy of cancer. Res. Immunol. 142:425-429.
14. Finn, O.J. 2003. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3:630-641.
15. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity. 11:263-270.
16. Pardoll, D.M. 1998. Cancer vaccines. Nat. Med. 4:525-531.
17. Ribas, A., L.H. Butterfield, J.A. Glaspy, and J.S. Economou. 2003. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21:2415-2432.
18. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
19. Meidenbauer, N., J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen. 2003. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170:2161-2169.
20. Yee, C., J.A. Thompson, D. Byrd, S.R. Riddell, P. Roche, E. Celis, and P.D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA. 99:16168-16173.
21. Banchereau, J., B. Schuler-Thurner, A.K. Palucka, and G. Schuler. 2001. Dendritic cells as vectors for therapy. Cell. 106:271-274.
22. Gilboa, E., S.K. Nair, and H.K. Lyerly. 1998. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46:82-87.
23. Steinman, R.M., and M. Dhodapkar. 2001. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer. 94:459-473.
24. Dhodapkar, M.V., J. Krasovsky, R.M. Steinman, and N. Bhardwaj. 2000. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105:R9-K14.
25. Davis, I.D., M. Jefford, P. Parente, and J. Cebon. 2003. Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73:3-29.
26. Schuler, G., B. Schuler-Thurner, and R.M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138-147.
27. Timmerman, J.M., and R. Levy. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:507-529.
28. Banchereau, J., A.K. Palucka, M. Dhodapkar, S. Burkeholder, N. Taquet, A. Rolland, S. Taquet, S. Coquery, K.M. Wittkowski, N. Bhardwaj, et al. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451-6458.
29. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G.A. Fisher, M.M. Davis, and E.G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA. 98:8809-8814.
30. Geiger, J.D., R.J. Hutchinson, L.F. Hohenkirk, E.A. McKenna, G.A. Yanik, J.E. Levine, A.E. Chang, T.M. Braun, and J.J. Mule. 2001. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61:8513-8519.
31. Hsu, F.J., C. Benike, F. Fagnoni, T.M. Liles, D. Czerwinski, B. Taidi, E.G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
32. Mackensen, A., B. Herbst, J.L. Chen, G. Kohler, C. Noppen, W. Herr, G.C. Spagnoli, V. Cerundolo, and A. Lindemann. 2000. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer. 86:385-392.
33. Nair, S.K., M. Morse, D. Boczkowski, R.I. Cumming, L. Vasovic, E. Gilboa, and H.K. Lyerly. 2002. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann. Surg. 235:540-549.
34. Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
35. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-1678.
36. Palucka, A.K., M.V. Dhodapkar, S. Paczesny, S. Burkeholder, K.M. Wittkowski, R.M. Steinman, J. Fay, and J. Banchereau. 2003. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J. Immunother. 26:432-439.
37. Therasse, P., S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A.T. van Oosterom, M.C. Christian, et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92:205-216.
38. Wittkowski, K., E. Lee, R. Nussbaum, F. Chamian, and J.G. Krueger. 2004. Combining several ordinal measures in clinical studies. Stat. Med. 23:1579-1592.
39. Hajek, J., and Z. Sidak. 1967. Theory of Rank Tests. Elsevier, New York. 250 pp.
40. Wittkowski, K.M., E. Susser, and K. Dietz. 1998. The protective effect of condoms and nonoxynol-9 against HIV infection. Am. J. Public Health. 88:590-596.
41. Yee, C., P.A. Savage, P.P. Lee, M.M. Davis, and P.D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162:2227-2234.
42. Godelaine, D., J. Carrasco, S. Lucas, V. Karanikas, B. Schuler-Thurner, P.G. Coulie, G. Schuler, T. Boon, and A. Van Pel. 2003. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J. Immunol. 171:4893-4897.
43. Heiser, A., D. Coleman, J. Dannull, D. Yancey, M.A. Maurice, C.D. Lallas, P. Dahm, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109:409-417.
44. Brossart, P., S. Wirths, G. Stuhler, V.L. Reichardt, L. Kanz, and W. Brugger. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 96:3102-3108.
45. Yu, J.S., C.J. Wheeler, P.M. Zeltzer, H. Ying, D.N. Finger, P.K. Lee, W.H. Yong, F. Incardona, R.C. Thompson, M.S. Riedinger, et al. 2001. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61:842-847.
46. Su, Z., J. Dannull, A. Heiser, D. Yancey, S. Pruitt, J. Madden, D. Coleman, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2003. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63:2127-2133.
47. Timmerman, J.M., D.K. Czerwinski, T.A. Davis, F.J. Hsu, C. Benike, Z.M. Hao, B. Taidi, R. Rajapaksa, C.B. Caspar, C.Y. Okada, et al. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 99:1517-1526.
48. Romero, P., P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641-1650.
49. Lee, P.P., C. Yee, P.A. Savage, L. Fong, D. Brockstedt, J.S. Weber, D. Johnson, S. Swetter, J. Thompson, P.D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
50. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:705-715.
51. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
52. Waldmann, T.A., S. Dubois, and Y. Tagaya. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity. 14:105-110.
53. Waldmann, T.A., and Y. Tagaya. 1999. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17:19-49.